日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study

Talquetamab（一种GPRC5D×CD3双特异性抗体）治疗中国复发/难治性多发性骨髓瘤患者的疗效和安全性：来自MonumentTAL-1 1/2期研究

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2025.287334
An, Gang; Jin, Jie; Cai, Zhen; Jing, Hongmei; Fu, Chengcheng; He, Pengcheng; Xia, Zhongjun; Liu, Rui; Li, Liang; Gai, Xue; Zhang, Hong; Zhu, Dian; Luo, Xinchao; Sun, Binbin; Xu, Hongmei; Zhou, Longen; Campagna, Michela; Masterson, Tara J; Lau, Bonnie W; Renaud, Thomas; Heuck, Christoph; Singh, Indrajeet; Vishwamitra, Deeksha; Qiu, Lugui
多发性骨髓瘤
CD3
骨髓瘤
发表日期：2026
文献求助 收藏

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

达雷妥尤单抗一线治疗在真实世界环境中使多发性骨髓瘤患者获益：一项多中心回顾性倾向评分匹配研究

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-026-06808-5
Wang, Yun; Chen, Xiaoqin; Liang, Qi; Wang, Weida; Luo, Jun; Luo, Lin; Feng, Ru; Wei, Yongqiang; Tian, Yuyang; Du, Xin; Huang, Zhenqian; Hu, Guoyu; Fu, Xiangjun; Tao, Shi; Zhou, Jihao; Peng, Hongling; Su, Yongzhong; Zhang, Hongyu; Dong, Min; Lan, Mei; Sun, Zhiqiang; Wang, Xiuju; Zhou, Hui; Zhong, Liye; Peter Gale, Rober; Liang, Yang; Xia, Zhongjun
多发性骨髓瘤
骨髓瘤
发表日期：2026
文献求助 收藏

Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma

zevorcabtagene autoleucel（一种全人源BCMA靶向CAR-T细胞疗法）治疗复发/难治性多发性骨髓瘤患者的II期研究

期刊:Experimental Hematology & Oncology
影响因子:13.5
doi:10.1186/s40164-025-00710-y
Chen, Wenming; Fu, Chengcheng; Fang, Baijun; Liang, Aibin; Xia, Zhongjun; He, Yanjuan; Lu, Jin; Liu, Hui; Hou, Ming; Cai, Zhen; Yang, Wei; Hao, Siguo; Jiang, Songfu; Jing, Hongmei; Liu, Jing; Du, Xin; Fu, Rong; Mei, Heng; Zhu, Zunmin; Yang, Yanli; Liu, Hong; Meng, Xingxing; Rajakumaraswamy, Nishanthan; Yuan, Daijing; Wang, Huamao; Li, Zonghai
T细胞
多发性骨髓瘤
T细胞
骨髓瘤
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma.

骨髓免疫生态系统决定了浆细胞骨髓瘤中达雷妥尤单抗的获得性耐药性

期刊:Leukemia
影响因子:13.4
doi:10.1038/s41375-025-02712-5
Wang Yun, Chen Shuzhao, Liang Zhijian, Gale Robert Peter, Liu Shutong, Chen Xiaoqin, Chi Peidong, Song Yiling, Zhang Yingchun, Wang Weida, Li Juan, Xia Zhongjun, Liang Yang, Huang Xiaojun
细胞生物学
发表日期：2025
文献求助 收藏

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1

来自 MajesTEC-1 中国队列的 teclistamab 治疗复发/难治性多发性骨髓瘤中国患者的疗效、安全性和药代动力学研究

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.35665
Cai, Zhen; Xia, Zhongjun; He, Ai-Li; Dong, Yu-Jun; Wang, Yafei; Liao, Aijun; Song, Yang; Song Mm, Juanjuan; Uhlar, Clarissa; Chastain, Katherine; Watkins, Latisha; Luo, Xinchao; Huang, Lin; Niu, Zhuolu; Quijano Cardé, Natalia A; Guo, Yue; Xu, Hongmei; Verona, Raluca I; Zhou, Longen; Li, Jingyun; Fu, Weijun; Niu, Ting; Du, Juan
多发性骨髓瘤
TEC
骨髓瘤
发表日期：2025
文献求助 收藏

Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study

在初诊早期预后不良和晚期经典型霍奇金淋巴瘤患者中，同时使用抗PD-1抗体联合AVD方案较ABVD方案疗效更佳：一项回顾性匹配队列研究

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04041-z
Wu, Mengqiu; Sun, Peng; Zhao, Baitian; Yang, Hang; Xia, Yi; Nie, Man; Cai, Qingqing; Huang, Huiqiang; Huang, He; Xia, Zhongjun; Wang, Yu; Li, Zhiming; Liu, Panpan
淋巴瘤
PD-1
发表日期：2025
文献求助 收藏

Oxidative Stress Score as a Simplified Surrogate for Prognostic Stratification and Therapeutic Decision-Making in Multiple Myeloma

氧化应激评分作为多发性骨髓瘤预后分层和治疗决策的简化替代指标

期刊:Pharmaceuticals
影响因子:4.8
doi:10.3390/ph18060878
Liang, Qi; Zhang, Limei; Huang, Qianqian; Lv, Weiran; Liang, Zhijian; Liu, Shutong; Nie, Runcong; Xia, Zhongjun; Liang, Yang; Wang, Yun
多发性骨髓瘤
氧化应激
毒理研究
骨髓瘤
发表日期：2025
文献求助 收藏

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases

中国专家共识：静脉注射免疫球蛋白在血液疾病中的应用

期刊:Frontiers in Medicine
影响因子:3
doi:10.3389/fmed.2025.1544025
Guo, Zhi; Zhu, Jie; Wang, Jun; Wang, Liang; Tang, Feifei; Huang, Huiqiang; Xia, Zhongjun; Liu, Liqiong; Wang, Danyu; Zhong, Nan; Zhou, Huanhuan; Zhou, Zhaogui; Dai, Wei; Xu, Xiaojun; Zhou, Hao; Deng, Lijuan; Meng, Jingye; Sun, Zhiqiang; Shao, Liang; Cao, Yu J; Liu, Yansong; Qu, Rong; Li, Guowei; Chen, Peng; Zhang, Hongyan; Liang, Jing; Li, Yuhua; Liu, Jiajun; Xu, Zishan; Sung Inda, Soong; Xiang, Xiaochen; Wu, Qingming; Wang, Qiang
免疫/内分泌
发表日期：2025
文献求助 收藏

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study

新诊断多发性骨髓瘤患者循环肿瘤细胞≥2%的临床结局：一项多中心研究的启示

期刊:
影响因子:
doi:10.1080/07853890.2025.2496796
Liang, Dong; Yan, Yurong; Bai, Shenrui; Xu, Weiling; Wang, Qiaoli; Feng, Demei; Bu, Yuying; Zeng, Min; Nie, Xiaomiao; Feng, Yuan; Chen, Xiaoqin; Xia, Zhongjun; Liang, Yang; Jin, Fengyan; Wang, Hua
肿瘤
肿瘤免疫
多发性骨髓瘤
骨髓瘤
细胞生物学
肿瘤细胞
发表日期：2025
文献求助 收藏

Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations

全球 miRNA 分析揭示了导致亚洲和西方人群慢性淋巴细胞白血病发病率差异的关键分子

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2023.283181
Liu, Panpan; Wang, Kefeng; Li, Jianan; Ogasawara, Marcia A; Xia, Zhongjun; Wierda, William G; Keating, Michael J; Li, Yiqing; Huang, Peng
白血病
miRNA
细胞生物学
发表日期：2024
文献求助 收藏